摘要
To the Editor:Pemetrexed plus platinum(cisplatin or carboplatin)chemotherapy doublets are widely recommended as the standard first-line treatment for non-small cell lung cancer(NSCLC)with no identified genetic mutations.[1]However,their efficiency has been confirmed with a median survival of approximately 10.2 to 13.0 months and a 5-year survival rate of 13%to 15%.Initial chemotherapy with pemetrexed has been confirmed as an effective regimen for advanced lung adenocarcinoma without specific genetic biomarker predicting the benefit of pemetrexed efficacy.[2]Patients treated with pemetrexedbased regimens can also receive a single agent as maintenance treatment after the induction chemotherapy.
